1996
DOI: 10.1177/107327489600300202
|View full text |Cite
|
Sign up to set email alerts
|

Tamoxifen and Endometrial Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

1998
1998
2007
2007

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…Available data indicate, however, that tamoxifen can to some extent mimic E 2 action as well, and it has been reported to have some moderate estrogenic effects (Barakat 1996).…”
Section: Figmentioning
confidence: 98%
See 1 more Smart Citation
“…Available data indicate, however, that tamoxifen can to some extent mimic E 2 action as well, and it has been reported to have some moderate estrogenic effects (Barakat 1996).…”
Section: Figmentioning
confidence: 98%
“…Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly used in the management of patients with estrogen-dependent breast cancer (Barakat 1996).…”
Section: Introductionmentioning
confidence: 99%
“…In humans, there is now an accepted association between tamoxifen use and an increased risk of endometrial cancer, but as yet no definite association with an increased risk of any other malignancies (Jordan 1995b, Barakat 1996. Endometrial carcinoma In the mid 1980s, a number of authors reported the occurrence of endometrial cancers in patients with breast cancer receiving tamoxifen (Killackey et al 1985).…”
Section: Risk Of Second Malignancies With Tamoxifen Usementioning
confidence: 99%